bevacizumab

Conference Coverage

Atezolizumab Plus Bevacizumab Unlikely to be Cost-Effective Compared With Sorafenib for HCC

01/15/2021

Journal of Clinical Pathways

Research in Review

Switching From Docetaxel to Paclitaxel and Bevacizumab Improves PFS in NSCLC

12/08/2016

JCP Editors

Patients with non-squamous non-small cell lung cancer (NSCLC) have improved progression-free survival (PFS) if they switch from docetaxel to paclitaxel and bevacizumab treatments, according to new...

...

12/08/2016

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

September 21 ⁠–⁠ September 22

September 30 ⁠–⁠ October 2

October 1 ⁠–⁠ October 2

October 2 ⁠–⁠ October 5

October 5 ⁠–⁠ October 6

October 14 ⁠–⁠ October 16

October 16 ⁠–⁠ October 19

October 19 ⁠–⁠ October 20

October 26 ⁠–⁠ October 27

October 29 ⁠–⁠ November 2

See Full Calendar

bevacizumab

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products